The study, conducted at two tertiary oncology centers in Ankara, Turkey, and registered on ClinicalTrials.gov under identifier NCT06687330, enrolled 200 adults with metastatic cancer who had been discharged following an unplanned hospitalization. Each participant wore a wrist-worn activity tracker during the recovery period, and the investigators defined a prespecified 14-day postdischarge landmark window during which physical activity was quantified. The main exposure variable was deliberately simple: the median daily step count recorded during those two weeks. The primary outcome was unplanned readmission within 90 days of discharge, and the secondary outcome was all-cause mortality within the same period. Beyond these hard clinical endpoints, the team also examined whether postdischarge mobility correlated with patient-reported outcomes including health-related quality of life, sleep quality, anxiety, and depressive symptoms, measured with validated instruments such as the Pittsburgh Sleep Quality Index and the Hospital Anxiety and Depression Scale.

The raw numbers underscore how precarious this patient population is. Of the 200 evaluable patients, 86, or 43.0 percent, experienced an unplanned readmission within 90 days, and 56, or 28.0 percent, died within that same window. Against this backdrop, the step-count data proved remarkably discriminative. Receiver operating characteristic analysis, a statistical technique that evaluates how well a continuous measure separates patients who experience an event from those who do not, identified 3,013 steps per day as the optimal cutoff for predicting 90-day readmission. Patients whose median daily activity fell at or below this threshold had a readmission rate of 73.0 percent, compared with just 13.0 percent among those who moved more. Mortality told an equally sobering story: 47.0 percent of the low-activity group died within 90 days versus 9.0 percent of the more active group, differences that were highly statistically significant with p values below 0.001.

Perhaps the most important question for any proposed biomarker is whether the association holds up after accounting for other factors that influence outcomes, such as age, disease characteristics, and baseline health status. In multivariable analysis, low postdischarge step count remained independently associated with both endpoints. Patients in the low-activity group had an adjusted odds ratio of 22.9 for readmission, with a 95 percent confidence interval spanning 9.3 to 56.6, meaning that even at the conservative bounds of the estimate, low mobility was associated with a roughly ninefold to fifty-six-fold increase in the odds of returning to the hospital. For mortality, the adjusted hazard ratio was 5.46, with a 95 percent confidence interval of 2.54 to 11.74. The discrimination of the continuous measure was also strong: the area under the receiver operating characteristic curve, or AUC, was 0.86 for 90-day readmission and 0.83 for 90-day mortality. In clinical research, an AUC above 0.80 is generally considered indicative of good discriminative ability, placing wearable-derived step counts in territory rarely occupied by traditional clinician-rated assessments in this setting.

The study’s findings extended into the domain of patient-reported outcomes, linking objective mobility to the subjective experience of living with advanced cancer. Higher postdischarge activity was associated with better health-related quality of life, better sleep, and lower burdens of anxiety and depressive symptoms. The dose-response relationship was quantified in a clinically intuitive way: each additional 1,000 steps per day was associated with lower odds of poor sleep quality, clinically significant anxiety, and depressive symptoms. This aligns with a growing body of literature connecting physical activity with mental health. A 2024 systematic review and meta-analysis published in JAMA Network Open found that higher daily step counts were associated with lower rates of depression in adults, and prior work in general populations has documented links between step volume and sleep quality and psychological well-being. The new study extends these observations to one of the most medically fragile populations imaginable: patients with metastatic disease recovering from an acute hospitalization.

The rationale for using wearables in oncology has been building for years. Consumer wrist-worn devices have been shown in validation studies to provide reasonably accurate estimates of physical activity in research settings, and their low cost, scalability, and acceptability to patients make them attractive candidates for continuous monitoring outside the clinic. Earlier work in advanced cancer established the concept: a 2018 study in NPJ Digital Medicine demonstrated that wearable activity monitors could assess performance status and predict clinical outcomes in patients with advanced cancer, and subsequent research in metastatic prostate cancer and metastatic non-small cell lung cancer has shown that objectively measured daily activity correlates with treatment toxicity and survival. What distinguishes the new study is its focus on the postdischarge period, a transition that has historically been monitored through episodic touchpoints rather than continuous data streams, and its use of a prespecified, simple metric, the median daily step count over a defined window, rather than complex composite activity scores.

The clinical implications are substantial. Roughly 43 percent of patients in the cohort returned to the hospital within three months, and more than a quarter died, figures consistent with the known vulnerability of patients with metastatic cancer after unplanned admissions. If a $50 consumer wearable can flag, within two weeks of discharge, which patients carry the highest risk, oncology teams could in principle direct limited supportive care resources, including early follow-up visits, telehealth check-ins, palliative care consultations, home health services, and rehabilitation programs, to those who need them most. The study’s authors emphasize that this stratification concept is scalable and patient-centered: patients generate the data themselves simply by going about their lives, and the measurement requires no laboratory infrastructure or specialized clinical assessment. The finding that each additional 1,000 daily steps was associated with better sleep and fewer anxiety and depressive symptoms also suggests a possible pathway by which mobility and supportive care needs are intertwined, with declining activity serving as an early, integrated signal of physical and psychological deterioration.

The study also speaks to a broader tension in modern oncology: the mismatch between the episodic nature of clinical assessment and the continuous nature of patient deterioration. Performance status, the workhorse measure used to judge fitness for treatment and to stratify patients in trials, is assigned by a clinician at a moment in time and is known to diverge from patients’ own reports of their function. Research comparing clinician-assessed and patient-reported performance status in advanced cancer has shown meaningful discrepancies, and both are susceptible to recall bias, white-coat effects, and the compression of complex functional trajectories into single ordinal grades. Wearable-derived step counts, by contrast, are objective, timestamped, and granular, capturing the rhythm of daily life rather than a snapshot. In the context of the postdischarge period, when trajectories can change rapidly and in both directions, this continuous measurement may capture exactly the information that episodic assessments miss.

The investigators are careful to frame their findings as hypothesis-generating rather than practice-changing. This was an observational cohort study, and association does not establish causation. It is biologically plausible that low mobility directly contributes to poor outcomes, for example through accelerated muscle loss, deconditioning, venous thromboembolism, or worsening cardiopulmonary reserve. It is equally plausible, however, that falling step counts are a downstream marker of advancing disease, uncontrolled symptoms, or frailty, in which case the wearable is measuring the trajectory of decline rather than driving it. The authors also note that external validation in independent and more diverse populations is needed, along with prospective interventional studies before wearable-derived mobility measures can be used to guide supportive care strategies. Whether triggering clinical interventions based on step-count thresholds actually reduces readmissions or improves survival is a question only randomized trials can answer. Questions about data privacy, device adherence, equity of access to wearable technology, and the accuracy of consumer devices across body types and activity patterns will also need attention before deployment at scale.

The smartwatches used in the study were provided in kind by the Turkish Society of Medical Oncology, which had no role in the design, conduct, analysis, or reporting of the research, and the authors declared no competing interests. The trial’s design, a prospective, two-center cohort with a prespecified landmark analysis window and validated patient-reported outcome instruments, lends methodological weight to the findings, and the effect sizes observed are large enough that they are unlikely to be artifacts of confounding alone, even if residual confounding cannot be excluded. The study is also notable for its practical framing: rather than developing bespoke research-grade sensors, the team used off-the-shelf consumer devices, testing a workflow that could realistically be implemented in routine oncology care.

As digital health technologies continue to permeate the cancer care continuum, from remote symptom monitoring to smartphone-assessed activity in early-phase trials, this study adds a compelling data point to the case that the humble step count deserves a place among the vital signs of oncology. For patients with metastatic cancer navigating the precarious weeks after a hospital discharge, the number of steps they take each day may encode, in real time, information about their trajectory that no clinic visit can capture. The next challenge for the field will be to prove that acting on that information, with earlier outreach, tailored rehabilitation, or intensified supportive care, actually changes outcomes. If it does, the postdischarge period, long a blind spot in cancer care, could become one of the first places where continuous, patient-generated health data moves from novelty to standard of practice.

The Value of a Statistical Life is a theoretical construct used by economists to quantify the monetary benefit individuals place on marginal reductions in mortality risk. Simply put, it aggregates how people value small decreases in the probability of death to estimate a monetary figure that society as a whole might be willing to pay for policies that save lives. This measurement is crucial for evaluating regulations like the Clean Air Act, where the direct effects—reducing pollutants such as particulate matter and ozone—translate into fewer premature deaths and improved overall health. Neill’s commentary critically examines the assumptions embedded in traditional VSL calculations and their implications for interpreting the economic returns of environmental policy.

One of the fundamental challenges Neill raises is the inherent uncertainty and variability in estimating VSL. Different studies, employing varied methodologies and data sources, produce a wide range of values for the VSL, leading to divergent conclusions about the economic benefits of pollution control. For example, VSL estimates can vary by age, income level, geographic region, and cultural factors, raising important questions about whose life is “valued” and how these choices affect policy evaluations. The commentary urges policymakers and economists to carefully consider whether a one-size-fits-all approach to VSL adequately captures the distributional and ethical complexities involved in environmental regulation.

Moreover, Neill highlights the dynamic nature of the VSL over time, considering how advancements in healthcare, risk perception, and demographic changes influence people’s willingness to pay for risk reductions. In the context of the Clean Air Act, where benefits accrue over decades, static VSL estimates may underrepresent the true economic value of improved air quality. The commentary proposes incorporating time-variant VSL measures and sensitivity analyses into benefit-cost frameworks to better reflect the realities of long-term environmental policymaking.

The implications of these insights become particularly salient when assessing the Clean Air Act’s benefit estimations published by agencies such as the Environmental Protection Agency (EPA). Traditional analyses often attribute billions of dollars in health benefits to the CAA, primarily based on reductions in premature mortality. However, Neill cautions that these numbers hinge critically on the chosen VSL assumptions. Adjusting the VSL upward or downward can dramatically shift the perceived cost-effectiveness of regulations, potentially influencing political debates and regulatory decisions.

Neill’s commentary also touches upon the role of equity in VSL application, recognizing that the uniform treatment of statistical lives may overlook significant inequalities in exposure to pollution and health vulnerabilities. Populations residing near high-emission areas or with limited access to healthcare often bear disproportionate risks, yet standard VSL-based analyses might not fully capture these disparities. This raises profound ethical and policy questions: Should VSL calculations be adapted to account for environmental justice considerations? How can regulatory frameworks incorporate these adjustments without compromising analytical rigor?

Another critical aspect discussed is the integration of VSL into multi-criteria decision analyses that go beyond mortality risk to include morbidity benefits, ecosystem impacts, and social welfare considerations. While VSL remains a powerful tool for translating mortality risk into monetary terms, Neill emphasizes the need for comprehensive frameworks that also encompass the broad spectrum of benefits arising from cleaner air, such as improved labor productivity, reduced healthcare costs, and enhanced quality of life. This holistic approach can provide a more accurate picture of the Clean Air Act’s value to society.

The commentary delves into technical critiques of commonly used VSL estimation methods, including revealed preference techniques that infer values from wage-risk tradeoffs in labor markets, and stated preference surveys that directly ask individuals about their willingness to pay for risk reductions. Each method possesses unique strengths and limitations: revealed preference studies may be confounded by unobserved variables and labor market imperfections, whereas stated preference surveys can suffer from hypothetical bias or framing effects. Neill’s analysis advocates for methodological triangulation and improved data collection to refine VSL estimates.

Neill also addresses the question of discounting future benefits, a pivotal element in cost-benefit analyses of environmental regulation. Since the Clean Air Act yields mortality and morbidity improvements spread across years or decades, the choice of discount rate significantly affects the present value of benefits. A higher discount rate diminishes the value of future lives saved, potentially undervaluing long-term environmental protections. The commentary suggests that VSL analyses incorporate discounting schemes that reflect social preferences and intergenerational equity concerns to ensure balanced policy assessments.

Importantly, Neill critiques the reliance on aggregate VSL measures in regulatory impact assessments, which can mask heterogeneity in risk preferences and economic behavior across different subpopulations. For instance, individuals with higher income or education levels may express different willingness to pay for risk reduction compared to marginalized or economically disadvantaged groups. Such heterogeneity underscores the importance of disaggregated analyses that capture nuanced social preferences, thus informing more equitable policy designs.

In the context of rapid technological change and evolving epidemiological profiles, Neill posits that the VSL framework must also evolve to account for emerging health threats and environmental challenges. The Clean Air Act’s rigid VSL assumptions may insufficiently consider the increased mortality risks posed by climate change, wildfire smoke, and novel pollutants. Incorporating adaptive VSL models responsive to such shifts could enhance the relevance and accuracy of policy evaluations.

The commentary concludes with a call for interdisciplinary collaboration among economists, epidemiologists, environmental scientists, and ethicists to enrich VSL methodologies and their application. By integrating diverse perspectives and state-of-the-art scientific evidence, economic valuations of environmental policies like the Clean Air Act can better capture complex realities, ultimately supporting more informed and just decision-making.

Neill’s nuanced exploration of VSL’s application to the Clean Air Act reaffirms the critical role economic analysis plays in understanding the benefits of environmental regulation. However, it also signals caution against complacency in treating VSL as a fixed or universally applicable measure. As the scientific community and policymakers grapple with environmental and public health challenges of unprecedented scale, refining these valuation tools remains not only an academic exercise but a societal imperative.

The commentary’s findings echo a broader trend in environmental economics questioning traditional cost-benefit paradigms and advocating for frameworks that recognize uncertainty, equity, and complexity. As Neill articulates, the path forward involves both methodological rigor and ethical introspection, ensuring that valuation metrics do not merely quantify benefits but also resonate with the lived experiences and values of diverse populations.

Ultimately, the insights gleaned from this commentary underscore that while the Clean Air Act has delivered substantial health and economic benefits, fully capturing its magnitude requires continual refinement of the underlying economic instruments. The challenge resides in balancing technical precision with social relevance, a task that will define the future discourse on environmental policy evaluation.

Subject of Research: Economic valuation of public health benefits from the Clean Air Act using the Value of a Statistical Life
Article Title: Using the Value of a Statistical Life to Measure the Benefit from the Clean Air Act: Comment
Article References:

Neill, J.R. Using the Value of a Statistical Life to Measure the Benefit from the Clean Air Act: Comment. Atl Econ J 52, 39–44 (2024). https://doi.org/10.1007/s11293-024-09796-x

Image Credits: AI Generated

The longstanding approach to medical evaluation emphasizes the diagnosis and treatment of discrete diseases, a methodology which, while effective in many respects, often overlooks the intricate interplay between comorbidities and their cumulative impact on overall health. Dr. Shabnam Salimi, a physician-scientist and the study’s lead author, argues that this siloed perspective hinders comprehensive understanding of aging as a multidimensional biological phenomenon. The Health Octo Tool, she explains, represents a paradigm shift by encapsulating physiological decline through an “aging-based framework” that integrates systemic organ function and cumulative damage rather than isolated pathologies.

At the heart of the tool lies the concept of “health entropy,” a measurable index that captures the degree of molecular and cellular deterioration accrued over time within the body. This concept derives from thermodynamic principles, where entropy signifies disorder, thereby analogizing the biological decline seen in aging tissues and organ systems. By quantifying health entropy, researchers equate it to an individual’s overall physical resilience and rate of biological aging, providing a biomarker more predictive of functional outcomes than chronological age or singular disease markers.

The research team utilized the extensive dataset from the Baltimore Longitudinal Study on Aging (BLSA), which tracks adults’ health trajectories over decades. From these data, they instituted a metric called the Body Organ Disease Number (BODN), which indexes the extent of organ system involvement across fourteen domains including cardiovascular, respiratory, neurological, and oncological statuses. This multidimensional score operationalizes disease burden in a manner that appreciates not just presence but distribution of dysfunction across organ systems.

Extending the analytical framework, the investigators introduced the Bodily System-Specific Age, which estimates the biological age of individual organ systems based on their unique functional decline patterns. Complementing this, the Bodily-Specific Clock quantifies intrinsic biological aging within each organ system. These refined metrics illuminate an essential finding: organ systems do not age synchronously. Rather, differential aging rates exist within a single individual, highlighting the heterogeneity that traditional models often obscure.

Building on these system-specific insights, the researchers synthesized composite measures— the Body Clock and Body Age—that reflect the aggregate intrinsic aging across the entire organism. Distinct from chronological age, these metrics embody the rate and extent of physiological decline, enabling a more nuanced assessment of an individual’s health trajectory. This comprehensive approach transcends the constraints of disease-centric evaluation, positing aging itself as a quantifiable and targetable biological process.

Recognizing functional decline as a critical element of aging, the study further innovates through the creation of Speed-Body Clock and Speed-Body Age indices. These associate biological aging rates with mobility decline, operationalized through walking speed — a well-established predictor of morbidity and mortality in older adults. Similarly, Disability-Body Clock and Disability Body Age metrics correlate intrinsic aging with cognitive and physical disability risk, thus bridging the gap between biological age and clinical outcomes.

Perhaps most strikingly, the Health Octo Tool reveals the outsized influence of ostensibly minor conditions on long-term aging trajectories. Early-life untreated hypertension, traditionally regarded as a manageable risk factor, emerged as a potent driver of accelerated biological aging. This observation underscores the potential for early intervention to modulate aging pathways and improve lifespan and healthspan, aligning with emerging geroscience goals.

The research team is actively developing a digital platform to operationalize these findings, aiming to provide clinicians and their patients with a user-friendly interface to calculate body and organ-specific ages. The application will allow users to monitor aging metrics longitudinally and evaluate the efficacy of lifestyle adjustments or pharmacological interventions in real time. Such technological integration holds promise for personalized medicine strategies that dynamically respond to an individual’s biological aging profile.

Senior authors Daniel Raftery, professor of anesthesiology and pain medicine at UW, and Luigi Ferrucci, scientific director at the National Institute on Aging, emphasize the transformative potential of this tool. By enabling quantitative tracking of aging processes, the Health Octo Tool may catalyze shifts in clinical practice, research, and public health policy, ultimately fostering interventions that prolong vigor and reduce age-associated disability.

The study was supported by a grant from the National Institutes of Health’s National Institute on Aging, underscoring the importance of federal funding in advancing translational geroscience. Moreover, the Health Octo Tool is currently under provisional patent by Dr. Salimi, with plans to disseminate it digitally to the broader research community, heralding a new era of accessible and data-driven aging assessments.

This work challenges prevailing medical dogmas by modeling aging as a complex, system-wide phenomenon rather than a linear consequence of individual diseases. Its multifaceted metrics offer clinicians and researchers a powerful toolkit to interrogate biological aging, elucidate mechanisms of resilience and decline, and tailor interventions aimed at extending healthy longevity.

As the global population ages, such innovative approaches are critical to addressing the burgeoning burden of chronic disease and disability. By quantifying aging in a clinically meaningful way, the Health Octo Tool lays the groundwork for precision geriatrics that is anticipatory, personalized, and potentially transformative for human healthspan.

Subject of Research: People

Article Title: Health octo tool matches personalized health with rate of aging

News Publication Date: 5-May-2025

Web References:

• Nature Communications paper: https://www.nature.com/articles/s41467-025-58819-x
• Baltimore Longitudinal Study on Aging: https://www.nia.nih.gov/research/labs/blsa
• UW Medicine Healthy Aging & Longevity Research Institute: https://halo.dlmp.uw.edu/

References:
Raftery D, Salimi S, Ferrucci L, et al. Health octo tool matches personalized health with rate of aging. Nature Communications. 2025; https://doi.org/10.1038/s41467-025-58819-x

Image Credits: Danijel Djukovic/Raftery Lab UW Medicine

Keywords: Human health, Older adults, Geriatrics